Astrazeneca Pharma India, 506820, ASTRAZEN Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

16,242.13
198.27
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

15,745.34
0.37%
23.91

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

9.62
9.27
17.16

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
8.85
16.44

PAT CAGR (%)

10 Years
5 Years
3 Years

-
17.47
37.89

P:E (Median)

8 Years
5 Years
3 Years

103.95
103.76
98.76

P:BV (Average)

8 Years
5 Years
3 Years

19.26
19.26
17.89

EV:EBITDA (Average)

8 Years
5 Years
3 Years

59.58
62.19
61.12

Earnings Forecasts:

Description 2024 2025 2026 2027
Adj EPS 64.6
P/E Ratio 100.47
Revenue 1296
EBITDA 184
Net Income 162
ROA 15.7
P/Bk Ratio 22.79
ROE 24.84
FCFF 48.68
FCFF Yield 0.31

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Sep 24 Sep 23 Var% Jun 24 Jun 23 Var% Mar 24 Mar 23 Var% Dec 23 Dec 22 Var%
Net Sales 408.00 311.07 31.16% 387.52 295.47 31.15% 383.20 284.70 34.60% 305.79 249.81 22.41%
Expenses 355.46 258.31 37.61% 349.45 228.23 53.11% 333.81 224.86 48.45% 290.73 213.22 36.35%
EBITDA 52.54 52.76 -0.42% 38.07 67.24 -43.38% 49.39 59.85 -17.48% 15.06 36.59 -58.84%
EBIDTM 12.88% 16.96% 9.82% 22.76% 12.89% 21.02% 4.92% 14.65%
Other Income 8.15 8.37 -2.63% 8.35 8.10 3.09% 8.73 8.00 9.12% 9.66 7.20 34.17%
Interest 0.34 0.50 -32.00% 0.11 0.15 -26.67% 0.00 0.09 -100.00% 0.61 0.20 205.00%
Depreciation 9.32 3.68 153.26% 3.91 3.79 3.17% 3.76 4.25 -11.53% 3.70 4.13 -10.41%
PBT 51.03 73.38 -30.46% -15.16 71.40 - 54.35 23.28 133.46% 20.40 39.46 -48.30%
Tax 12.60 21.01 -40.03% -3.37 17.54 - 14.88 6.01 147.59% 4.60 10.15 -54.68%
PAT 38.43 52.37 -26.62% -11.79 53.86 - 39.48 17.27 128.60% 15.80 29.31 -46.09%
PATM 9.42% 16.84% -3.04% 18.23% 10.30% 6.07% 5.17% 11.73%
EPS 15.37 20.95 -26.63% -4.72 21.54 - 15.79 6.91 128.51% 6.32 11.72 -46.08%

Description Jun 24 Jun 23 Var% Mar 24 Mar 23 Var% Dec 23 Dec 22 Var% Sep 23 Sep 22 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 1,484.51 1,295.53 1,002.97 805.60 813.56 831.81 728.29 571.00 543.71 563.73 517.07 Net Sales Growth 30.10% 29.17% 24.50% -0.98% -2.19% 14.21% 27.55% 5.02% -3.55% 9.02% Cost Of Goods Sold 818.21 590.03 355.22 305.28 287.30 299.97 226.73 178.21 171.18 194.81 194.23 Gross Profit 666.30 705.50 647.75 500.32 526.26 531.84 501.56 392.79 372.53 368.93 322.84 GP Margin 44.88% 54.46% 64.58% 62.11% 64.69% 63.94% 68.87% 68.79% 68.52% 65.44% 62.44% Total Expenditure 1,329.45 1,111.08 837.85 719.42 678.09 711.11 656.99 524.71 506.77 547.31 528.48 Power & Fuel Cost - 4.87 5.54 8.10 7.37 7.72 8.27 8.30 7.68 7.43 8.51 % Of Sales - 0.38% 0.55% 1.01% 0.91% 0.93% 1.14% 1.45% 1.41% 1.32% 1.65% Employee Cost - 241.45 259.10 230.21 219.54 216.70 197.40 150.39 162.04 169.35 159.84 % Of Sales - 18.64% 25.83% 28.58% 26.99% 26.05% 27.10% 26.34% 29.80% 30.04% 30.91% Manufacturing Exp. - 89.46 76.04 57.12 49.32 40.81 49.58 50.67 36.40 25.82 17.69 % Of Sales - 6.91% 7.58% 7.09% 6.06% 4.91% 6.81% 8.87% 6.69% 4.58% 3.42% General & Admin Exp. - 66.30 56.66 40.04 40.69 65.54 74.09 46.49 55.04 59.10 63.77 % Of Sales - 5.12% 5.65% 4.97% 5.00% 7.88% 10.17% 8.14% 10.12% 10.48% 12.33% Selling & Distn. Exp. - 97.48 71.57 62.09 55.94 65.13 88.18 81.07 62.56 84.65 77.77 % Of Sales - 7.52% 7.14% 7.71% 6.88% 7.83% 12.11% 14.20% 11.51% 15.02% 15.04% Miscellaneous Exp. - 21.49 13.72 16.58 17.93 15.24 12.74 9.58 11.87 6.16 77.77 % Of Sales - 1.66% 1.37% 2.06% 2.20% 1.83% 1.75% 1.68% 2.18% 1.09% 1.29% EBITDA 155.06 184.45 165.12 86.18 135.47 120.70 71.30 46.29 36.94 16.42 -11.41 EBITDA Margin 10.45% 14.24% 16.46% 10.70% 16.65% 14.51% 9.79% 8.11% 6.79% 2.91% -2.21% Other Income 34.89 34.80 26.10 14.76 12.84 12.99 16.29 12.25 14.39 6.77 5.85 Interest 1.06 1.20 0.63 0.95 1.09 1.14 0.00 0.00 0.00 0.00 0.00 Depreciation 20.69 14.94 16.26 16.95 20.13 18.58 14.92 14.74 15.83 17.43 15.28 PBT 110.62 203.11 174.33 83.04 127.09 113.97 72.67 43.80 35.50 5.76 -20.84 Tax 28.71 58.03 34.81 21.44 33.79 41.76 18.22 17.89 15.45 0.50 0.00 Tax Rate 25.95% 26.43% 25.96% 25.82% 26.59% 36.64% 25.07% 40.84% 43.52% 8.68% 0.00% PAT 81.92 161.51 99.29 61.60 93.30 72.21 54.45 25.91 20.05 5.26 -20.84 PAT before Minority Interest 81.92 161.51 99.29 61.60 93.30 72.21 54.45 25.91 20.05 5.26 -20.84 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 5.52% 12.47% 9.90% 7.65% 11.47% 8.68% 7.48% 4.54% 3.69% 0.93% -4.03% PAT Growth -46.39% 62.66% 61.19% -33.98% 29.21% 32.62% 110.15% 29.23% 281.18% - EPS 32.77 64.60 39.72 24.64 37.32 28.88 21.78 10.36 8.02 2.10 -8.34

Results Balance Sheet

Standalone Figures in Rs. Crores

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 711.92 588.69 511.39 456.17 364.44 300.80 246.93 222.87 156.01 150.76 Share Capital 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 Total Reserves 703.63 581.12 504.44 449.58 357.85 293.70 239.85 216.22 151.01 145.76 Non-Current Liabilities 97.83 68.99 73.63 44.60 44.13 22.75 109.73 88.68 38.96 1.02 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 116.30 85.97 84.91 50.50 49.47 46.11 142.28 128.90 37.70 0.00 Current Liabilities 467.15 484.40 392.30 373.43 367.10 267.60 218.67 202.05 234.05 259.82 Trade Payables 196.51 227.88 190.44 178.37 209.72 168.20 127.20 87.66 94.63 111.27 Other Current Liabilities 110.53 111.95 94.23 82.58 71.06 54.38 39.41 69.84 121.08 111.60 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Short Term Provisions 160.11 144.57 107.63 112.48 86.32 45.02 52.06 44.55 18.33 36.95 Total Liabilities 1,276.90 1,142.08 977.32 874.20 775.67 591.15 575.33 513.60 429.02 411.60 Net Block 66.68 68.86 74.49 80.96 71.53 74.83 75.46 86.84 97.36 100.99 Gross Block 187.13 179.12 168.83 159.78 132.84 119.83 105.85 102.57 203.76 191.44 Accumulated Depreciation 120.45 110.26 94.34 78.82 61.31 45.00 30.39 15.73 106.40 90.46 Non Current Assets 234.16 206.14 212.00 185.51 193.49 177.81 242.69 250.34 161.95 148.33 Capital Work in Progress 0.27 1.33 2.20 4.02 24.24 6.90 3.57 4.81 6.31 12.21 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 167.21 135.95 135.31 100.52 97.71 95.83 163.39 158.27 57.68 34.55 Other Non Current Assets 0.00 0.00 0.00 0.01 0.01 0.25 0.27 0.42 0.61 0.59 Current Assets 1,042.74 935.94 765.32 688.69 582.18 413.34 332.64 263.26 267.07 263.26 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 227.88 190.21 140.22 159.80 165.15 118.10 113.15 57.71 76.73 86.13 Sundry Debtors 153.13 107.52 85.89 85.19 83.21 79.75 54.63 43.00 83.14 42.77 Cash & Bank 505.84 500.48 448.46 352.35 252.52 173.30 125.92 115.58 76.83 25.08 Other Current Assets 155.89 13.56 12.64 14.05 81.30 42.19 38.94 46.97 30.37 109.27 Short Term Loans & Adv. 142.66 124.17 78.11 77.30 61.45 29.25 30.87 23.43 20.22 107.46 Net Current Assets 575.59 451.54 373.02 315.26 215.08 145.74 113.97 61.21 33.03 3.44 Total Assets 1,276.90 1,142.08 977.32 874.20 775.67 591.15 575.33 513.60 429.02 411.59

Cash Flow

Standalone Figures in Rs. Crores

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 27.87 58.29 100.80 104.78 87.42 54.98 8.79 38.10 56.99 -45.70 PBT 219.54 134.10 83.04 127.09 113.97 72.67 43.80 35.50 5.76 -20.84 Adjustment -7.07 -4.80 9.66 14.20 9.75 7.62 3.39 14.61 12.11 8.58 Changes in Working Capital -128.17 -30.19 32.89 -3.95 -2.66 9.81 -34.25 -0.24 42.09 -32.58 Cash after chg. in Working capital 84.30 99.11 125.59 137.34 121.06 90.10 12.94 49.87 59.97 -44.83 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -56.43 -40.82 -24.79 -32.56 -33.64 -35.12 -4.15 -11.77 -2.98 -0.87 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 21.74 18.11 4.74 173.03 -170.80 4.28 -9.36 0.25 -3.61 -18.64 Net Fixed Assets -6.95 -9.42 -7.23 -6.72 -30.35 -17.31 -2.04 102.69 -6.42 -24.59 Net Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Others 28.69 27.53 11.97 179.75 -140.45 21.59 -7.32 -102.44 2.81 5.95 Cash from Financing Activity -44.38 -24.48 -9.46 -8.97 -6.36 0.00 0.00 0.00 -0.51 0.00 Net Cash Inflow / Outflow 5.23 51.92 96.08 268.84 -89.74 59.26 -0.57 38.35 52.87 -64.34 Opening Cash & Equivalents 500.34 448.42 352.34 83.50 173.24 113.98 114.55 76.20 23.33 87.68 Closing Cash & Equivalent 505.57 500.34 448.42 352.34 83.50 173.24 113.98 114.55 76.20 23.33

Financial Ratios

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 283.45 234.45 203.78 181.83 145.14 119.48 97.94 88.49 62.41 60.30 ROA 13.35% 9.37% 6.65% 11.31% 10.57% 9.34% 4.76% 4.25% 1.25% -5.04% ROE 24.95% 18.13% 12.78% 22.83% 21.83% 20.03% 11.12% 10.63% 3.43% -12.93% ROCE 33.94% 24.49% 17.36% 31.24% 34.61% 26.53% 18.65% 18.74% 3.76% -12.93% Fixed Asset Turnover 7.11 5.79 4.93 5.58 6.58 6.45 5.49 3.58 2.88 2.91 Receivable days 36.53 35.03 38.57 37.62 35.75 33.67 31.15 41.96 40.32 33.27 Inventory Days 58.60 59.85 67.64 72.59 62.15 57.95 54.51 44.72 52.15 63.23 Payable days 131.27 214.92 220.48 246.52 99.66 91.40 73.21 75.53 75.14 85.66 Cash Conversion Cycle -36.14 -120.04 -114.26 -136.32 -1.76 0.22 12.45 11.15 17.33 10.84 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Interest Cover 183.95 213.86 88.41 117.60 100.97 0.00 0.00 0.00 0.00 0.00

Top Investors:

nippon life (various schemes)

tejas bhalchandra trivedi

shivani tejas trivedi

icici prudential (various schemes)

investor education and protection fund (iepf)

Annual Reports:

News Update:

AstraZeneca Pharma to launch Breztri Aerosphere in January 2025
19th Nov 2024, 09:25 AM

In December 2023, the company had received import and market permission in Form CT-20 from the Drugs Controller General of India for Breztri Aerosphere
Read More
AstraZeneca Pharma gets nod to import Durvalumab solution
24th Sep 2024, 09:44 AM

The receipt of this permission paves way for the launch of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) in India for the specified additional indication
Read More

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update:

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update: